The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
暂无分享,去创建一个
F. Saad | G. Andriole | K. Miller | A. Armstrong | C. Higano | B. Tombal | C. Sternberg | Choung-Soo Kim | Y. Loriot | P. Iversen | T. Beer | J. D. de Bono | G. Kimura | C. Evans | S. Bhattacharya | F. Perabo | H. Mansbach | T. Keane | S. Noonberg
[1] F. Saad,et al. 753OFINAL OVERALL SURVIVAL (OS) ANALYSIS OF COU-AA-302, A RANDOMIZED PHASE 3 STUDY OF ABIRATERONE ACETATE (AA) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) WITHOUT PRIOR CHEMOTHERAPY. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] F. Zustovich,et al. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. , 2014, Critical reviews in oncology/hematology.
[3] F. Saad,et al. Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.
[4] R. DiPaola,et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Scher,et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer , 2013, Prostate Cancer and Prostatic Disease.
[6] I. Tannock,et al. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. , 2014, European urology.
[7] F. Stagno,et al. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy : additional analyses from the AFFIRM randomized clinical trial , 2014 .
[8] C. Mathers,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .
[9] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[10] M L Kilgore,et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006 , 2011, Prostate Cancer and Prostatic Diseases.
[11] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[12] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[13] I. Tannock,et al. Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer , 2009, Clinical Cancer Research.
[14] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.